Search Results - "Balar, Arjun"

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy by Rosenberg, Jonathan E, O'Donnell, Peter H, Balar, Arjun V, McGregor, Bradley A, Heath, Elisabeth I, Yu, Evan Y, Galsky, Matthew D, Hahn, Noah M, Gartner, Elaina M, Pinelli, Juan M, Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P

“…Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated…”
Get full text

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors by Tagawa, Scott T, Balar, Arjun V, Petrylak, Daniel P, Kalebasty, Arash Rezazadeh, Loriot, Yohann, Fléchon, Aude, Jain, Rohit K, Agarwal, Neeraj, Bupathi, Manojkumar, Barthelemy, Philippe, Beuzeboc, Philippe, Palmbos, Phillip, Kyriakopoulos, Christos E, Pouessel, Damien, Sternberg, Cora N, Hong, Quan, Goswami, Trishna, Itri, Loretta M, Grivas, Petros

“…Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited…”
Get full text

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study by Balar, Arjun V, Kamat, Ashish M, Kulkarni, Girish S, Uchio, Edward M, Boormans, Joost L, Roumiguié, Mathieu, Krieger, Laurence E M, Singer, Eric A, Bajorin, Dean F, Grivas, Petros, Seo, Ho Kyung, Nishiyama, Hiroyuki, Konety, Badrinath R, Li, Haojie, Nam, Kijoeng, Kapadia, Ekta, Frenkl, Tara, de Wit, Ronald

“…Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by intravesical BCG immunotherapy…”
Get full text

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial by Yu, Evan Y, Petrylak, Daniel P, O'Donnell, Peter H, Lee, Jae-Lyun, van der Heijden, Michiel S, Loriot, Yohann, Stein, Mark N, Necchi, Andrea, Kojima, Takahiro, Harrison, Michael R, Hoon Park, Se, Quinn, David I, Heath, Elisabeth I, Rosenberg, Jonathan E, Steinberg, Joyce, Liang, Shang-Ying, Trowbridge, Janet, Campbell, Mary, McGregor, Bradley, Balar, Arjun V

“…Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients…”
Get full text

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial by Rosenberg, Jonathan E, Dr, Hoffman-Censits, Jean, MD, Powles, Tom, Prof, van der Heijden, Michiel S, Prof, Balar, Arjun V, MD, Necchi, Andrea, MD, Dawson, Nancy, Prof, O'Donnell, Peter H, MD, Balmanoukian, Ani, MD, Loriot, Yohann, MD, Srinivas, Sandy, MD, Retz, Margitta M, Prof, Grivas, Petros, MD, Joseph, Richard W, MD, Galsky, Matthew D, MD, Fleming, Mark T, MD, Petrylak, Daniel P, Prof, Perez-Gracia, Jose Luis, MD, Burris, Howard A, MD, Castellano, Daniel, MD, Canil, Christina, MD, Bellmunt, Joaquim, MD, Bajorin, Dean, Prof, Nickles, Dorothee, PhD, Bourgon, Richard, PhD, Frampton, Garrett M, PhD, Cui, Na, PhD, Mariathasan, Sanjeev, PhD, Abidoye, Oyewale, MD, Fine, Gregg D, MD, Dreicer, Robert, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we…”
Get full text

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study by Balar, Arjun V, Castellano, Daniel, O'Donnell, Peter H, Grivas, Petros, Vuky, Jacqueline, Powles, Thomas, Plimack, Elizabeth R, Hahn, Noah M, de Wit, Ronald, Pang, Lei, Savage, Mary J, Perini, Rodolfo F, Keefe, Stephen M, Bajorin, Dean, Bellmunt, Joaquim

“…More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction,…”
Get full text

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer by Vuky, Jacqueline, Balar, Arjun V, Castellano, Daniel, O'Donnell, Peter H, Grivas, Petros, Bellmunt, Joaquim, Powles, Thomas, Bajorin, Dean, Hahn, Noah M, Savage, Mary J, Fang, Xiao, Godwin, James Luke, Frenkl, Tara L, Homet Moreno, Blanca, de Wit, Ronald, Plimack, Elizabeth R

“…The phase II single-arm KEYNOTE-052 study evaluated the efficacy and safety of first-line pembrolizumab for patients with locally advanced or metastatic…”
Get full text

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials by Bellmunt, Joaquim, de Wit, Ronald, Fradet, Yves, Climent, Miguel A, Petrylak, Daniel P, Lee, Jae-Lyun, Fong, Lawrence, Necchi, Andrea, Sternberg, Cora N, O'Donnell, Peter H, Powles, Thomas, Plimack, Elizabeth R, Bajorin, Dean F, Balar, Arjun V, Castellano, Daniel, Choueiri, Toni K, Culine, Stephane, Gerritsen, Winald, Gurney, Howard, Quinn, David I, Vuky, Jacqueline, Vogelzang, Nicholas J, Cristescu, Razvan, Lunceford, Jared, Saadatpour, Assieh, Loboda, Andrey, Ma, Junshui, Rajasagi, Mohini, Godwin, James Luke, Homet Moreno, Blanca, Grivas, Petros

“…In an exploratory analysis, we investigated the association between programmed death ligand 1 (PD-L1), tumor mutational burden (TMB), T-cell-inflamed gene…”
Get full text

Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma by Balar, Arjun V

Get more information

Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA by Akumalla, Saranya, Madison, Russell, Lin, Douglas I, Schrock, Alexa B, Yakirevich, Evgeny, Rosenzweig, Mark, Balar, Arjun V, Frampton, Garrett M, Edgerly, Claire, Erlich, Rachel L, Miller, Vincent A, Ganesan, Shridar, Ross, Jeffrey S, Ali, Siraj M

“…Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal soft tissue neoplasm often linked to mTOR pathway activation via TSC2 mutation. We analyzed…”
Get more information

Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply by Balar, Arjun V, Kamat, Ashish M, de Wit, Ronald

“…[...]the US Food and Drug Administration (FDA) excluded these patients from the final analysis because their disease and treatment histories did not meet the…”
Get full text

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer by Powles, Thomas, Carroll, Danielle, Chowdhury, Simon, Gravis, Gwenaelle, Joly, Florence, Carles, Joan, Fléchon, Aude, Maroto, Pablo, Petrylak, Daniel, Rolland, Frédéric, Cook, Natalie, Balar, Arjun V., Sridhar, Srikala S., Galsky, Matthew D., Grivas, Petros, Ravaud, Alain, Jones, Robert, Cosaert, Jan, Hodgson, Darren, Kozarewa, Iwanka, Mather, Richard, McEwen, Robert, Mercier, Florence, Landers, Dónal

“…Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC) 1 . AUC is characterized by several…”
Get full text

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer by IYER, Gopa, AL-AHMADIE, Hikmat, ZABOR, Emily C, JANAKIRAMAN, Manickam, GARCIA-GROSSMAN, Ilana R, HEGUY, Adriana, VIALE, Agnes, BOCHNER, Bernard H, REUTER, Victor E, BAJORIN, Dean F, MILOWSKY, Matthew I, TAYLOR, Barry S, SCHULTZ, Nikolaus, SOLIT, David B, HANRAHAN, Aphrothiti J, OSTROVNAYA, Irina, BALAR, Arjun V, KIM, Philip H, LIN, Oscar, WEINHOLD, Nils, SANDER, Chris

“…We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for…”
Get full text

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma by Teo, Min Yuen, Mota, Jose Mauricio, Whiting, Karissa A., Li, Han A., Funt, Samuel A., Lee, Chung-Han, Solit, David B., Al-Ahmadie, Hikmat, Milowsky, Matthew I., Balar, Arjun V., Pietzak, Eugene, Dalbagni, Guido, Bochner, Bernard H., Ostrovnaya, Irina, Bajorin, Dean F., Rosenberg, Jonathan E., Iyer, Gopa

“…Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas…”
Get full text

PD-1 and PD-L1 antibodies in cancer: current status and future directions by Balar, Arjun Vasant, Weber, Jeffrey S.

“…Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed…”
Get full text

Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma by Lattanzi, Michael, Balar, Arjun V.

“…Purpose of Review Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial…”
Get full text

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02 by Siefker-Radtke, Arlene O., Cho, Daniel C., Diab, Adi, Sznol, Mario, Bilen, Mehmet A., Balar, Arjun V., Grignani, Giovanni, Puente, Erika, Tang, Lily, Chien, David, Hoch, Ute, Choudhury, Arkopal, Yu, Danni, Currie, Sue L., Tagliaferri, Mary A., Zalevsky, Jonathan, Hurwitz, Michael E., Tannir, Nizar M.

“…Bempegaldesleukin plus nivolumab was well tolerated and showed antitumor activity in this preliminary investigation of first-line treatment in patients with…”
Get full text

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial by Larkin, James, Oya, Mototsugu, Martignoni, Marcella, Thistlethwaite, Fiona, Nathan, Paul, Ornstein, Moshe C, Powles, Thomas, Beckermann, Kathryn E, Balar, Arjun V, McDermott, David, Gupta, Sumati, Philips, George K, Gordon, Michael S, Uemura, Hirotsugu, Tomita, Yoshihiko, Wang, Jing, Michelon, Elisabete, di Pietro, Alessandra, Choueiri, Toni K

“…Abstract Background Progression-free survival was significantly longer in patients who received avelumab plus axitinib versus sunitinib as first-line treatment…”
Get full text

PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials by Hsu, Miles M., Balar, Arjun V.

“…Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint…”
Get full text

Phase II study of everolimus in metastatic urothelial cancer by Milowsky, Matthew I., Iyer, Gopa, Regazzi, Ashley M., Al‐Ahmadie, Hikmat, Gerst, Scott R., Ostrovnaya, Irina, Gellert, Lan L., Kaplan, Rana, Garcia‐Grossman, Ilana R., Pendse, Deepa, Balar, Arjun V., Flaherty, Anne Marie, Trout, Alisa, Solit, David B., Bajorin, Dean F.

“…What's known on the subject? and What does the study add? No recent advances have been made in the treatment of patients with advanced bladder cancer and, to…”
Get full text